| Literature DB >> 30759384 |
Ian L McWilliams1, Jennifer L Kielczewski2, Derek D C Ireland1, Jacob S Sykes1, Aaron P Lewkowicz1, Krishnamurthy Konduru3, Biying C Xu2, Chi-Chao Chan2, Rachel R Caspi2, Mohanraj Manangeeswaran4, Daniela Verthelyi5.
Abstract
Zaire Ebola virus (ZEBOV) survivors experience visual and CNS sequelae that suggests the ZEBOV glycoprotein can mediate neurotropism. Replication-competent rVSVΔG-ZEBOV-GP vaccine candidate is generally well tolerated; however, its potential neurotropism requires careful study. Here, we show that a single inoculation of rVSVΔG-ZEBOV-GP virus in neonatal C57BL/6 mice results in transient viremia, neurological symptoms, high viral titers in eyes and brains, and death. rVSVΔG-ZEBOV-GP infects the inner layers of the retina, causing severe retinitis. In the cerebellum, rVSVΔG-ZEBOV-GP infects neurons in the granular and Purkinje layers, resulting in progressive foci of apoptosis and neurodegeneration. The susceptibility to infection is not due to impaired type I IFN responses, although MDA5-/-, IFNβ-/-, and IFNAR1-/- mice have accelerated mortality. However, boosting interferon levels by co-administering poly(I:C) reduces viral titers in CNS and improves survival. Although these data should not be directly extrapolated to humans, they challenge the hypothesis that VSV-based vaccines are non-neurotropic. Published by Elsevier Inc.Entities:
Keywords: Ebola glycoprotein; Ebola vaccine; Ebola virus; VSV; VSV vaccine; ebolavirus; filovirus; innate immunity; neurotropism; neurovirulence; pseudotyped virus
Mesh:
Year: 2019 PMID: 30759384 PMCID: PMC6748882 DOI: 10.1016/j.celrep.2019.01.069
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423